ADCETRIS® (brentuximab vedotin) is a CD30-directed ADC indicated for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma (HL), systemic anaplastic large cell lymphoma (ALCL) and cutaneous T-cell lymphoma (CTCL) who have received prior systemic therapy.7–10 HL is characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, which comprise only a minority of cells in the tumor mass and express CD30 surface antigen. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.